

Astria STAR-0215-302 trial for Navenibart in Hereditary Angioedema

Submission date 19/09/2025	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 09/02/2026	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 10/03/2026	Condition category Haematological Disorders	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Researchers are looking for new ways to manage hereditary angioedema (HAE). HAE is a rare disorder that causes repeated and unpredictable attacks of swelling in the face, arms and legs, abdomen, genitals, and airway. These attacks can be severe, painful, disabling, and life-threatening. Treatments for HAE include medicines that help lessen the severity of an attack as it is happening (on-demand treatment) and medicines that help prevent HAE attacks (preventive treatment). These medicines often need to be taken frequently, which can be a burden for patients.

The drug being studied in this trial is called navenibart. Navenibart is a monoclonal antibody (an antibody is part of the body's immune defense system). It is being developed to prevent HAE attacks. It does this by blocking plasma kallikrein, an enzyme that produces a substance called bradykinin, which causes HAE attacks. Early results suggest that navenibart can potentially help patients by preventing HAE attacks. Astria Therapeutics Inc., the company that makes navenibart, wants to find out more about its effects in people with HAE, both adults (18 years or older) and adolescents (12 to 17 years old).

The main aim of this trial is to evaluate the safety and tolerability of navenibart in patients with HAE during long-term (more than 6 months and up to five years) use.

Who can participate?

Participants from STAR-0215-301 (ALPHA-ORBIT) who meet certain criteria can participate. About 145 participants with HAE will take part in the trial globally, including both adults (18 years or older) and adolescents (12 to 17 years old). There will be approximately 12 participants with HAE taking part in the UK.

What does the trial involve?

Participants will be in this trial for up to 5 years. All participants will receive navenibart. For adult participants who completed the ALPHA-ORBIT trial, this trial is divided into two parts. In Part 1, which will last at least 6 months for each participant, adults who received navenibart in ALPHA-ORBIT will continue at the same dose. Adults who received placebo in ALPHA-ORBIT will receive 600 mg of navenibart every 3 months. In Part 2, adults can change their navenibart dose in collaboration with the study doctors.

All adolescent participants will continue to receive navenibart at the same dose as ALPHA-ORBIT. Trial drug will be given subcutaneously (an injection given in the fatty tissue just under the skin using a small needle).

What are the possible benefits and risks of participating?

There may not be a direct medical benefit from receiving the study drug. A study participant's HAE may get better, stay the same, or even get worse.

It is possible that the results may not help individuals but the information we get from this study will help us improve treatment for people with HAE in the future.

Where is the study run from?

Astria Therapeutics, Inc (USA)

When is the study starting and how long is it expected to run for?

February 2026 to June 2031

Who is funding the study?

Astria Therapeutics, Inc (USA)

Who is the main contact?

alphaorbit_general@astriatx.com

Contact information

Type(s)

Public, Scientific

Contact name

None . Clinical Trial Inquiries

Contact details

22 Boston Wharf Road, 10th Floor

Boston

United States of America

MA 02210

+1 617 349 1971

alphaorbit_general@astriatx.com

Type(s)

Principal investigator

Contact name

Dr Patrick Yong

Contact details

Portsmouth Road

Frimley

United Kingdom

GU16 7UJ

+44 1276 604 604

patrick.yong@nhs.net

Additional identifiers

Clinical Trials Information System (CTIS)

2025-521142-22

Integrated Research Application System (IRAS)

1012485

Central Portfolio Management System (CPMS)

70310

Protocol serial number

STAR-0215-302

Study information

Scientific Title

A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE

Study objectives

Primary objective:

To assess the long-term safety and tolerability of navenibart in participants with hereditary angioedema (HAE)

Secondary objectives:

1. To assess the long-term clinical efficacy of navenibart as a preventive treatment for HAE in participants with HAE
2. To assess the quality of life associated with the use of navenibart in participants with HAE

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 09/12/2025, London - Chelsea Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; no telephone number provided; chelsea.rec@hra.nhs.uk), ref: 25/LO/0762

Primary study design

Interventional

Study design

Interventional non randomized

Study type(s)

Efficacy, Safety

Health condition(s) or problem(s) studied

Hereditary angioedema

Interventions

Adult participants will receive one of three dosing regimens:

Regimen 1: Participants will receive 600 mg of navenibart (STAR-0215) via subcutaneous injection every 3 months.

Regimen 2: Participants will receive 300 mg of navenibart (STAR-0215) via subcutaneous injection every 3 months.

Regimen 3: Participants will receive 600 mg of navenibart (STAR-0215) via subcutaneous injection every 6 months.

Adolescent participants will receive 300 mg of navenibart (STAR-0215) via subcutaneous injection every 3 months.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Navenibart 150mg/ml

Primary outcome(s)

Incidence of treatment-emergent adverse events measured using patient records at first dosing visit through final follow-up visit

Key secondary outcome(s)

First dosing visit through final follow-up visit measured using patient records:

1. Number of time-normalized investigator-confirmed HAE attacks
2. Number of moderate or severe investigator-confirmed HAE attacks
3. Number of investigator-confirmed HAE attacks that require on-demand treatment
4. Percent reduction in monthly investigator-confirmed HAE attacks
5. Time to first investigator-confirmed HAE attack after first dose
6. The number of participants responding to treatment, defined as a $\geq 50\%$, $\geq 70\%$, or $\geq 90\%$ reduction in investigator-confirmed HAE attack rate
7. Number of participants with no investigator-confirmed HAE attacks
8. Angioedema Quality of Life (AE-QoL) questionnaire total score

Completion date

30/06/2031

Eligibility

Key inclusion criteria

1. Participants from STAR-0215-301 who met one of the following conditions:
 - a. Completed STAR-0215-301 through the Day 181 visit
 - b. Withdrew from STAR-0215-301 and met all of the following criteria:
 - i. Received 2 doses of IP
 - ii. completed ≥ 2 months of trial follow-up after the second dose of IP
 - iii. Met other eligibility criteria as assessed by Investigator

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

12 Years

Upper age limit

120 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Participation in an investigational clinical trial other than STAR-0215- 301 in the 30 days or any exposure to an investigational drug (other than navenibart in STAR-0215-301) within 5 half-lives before informed consent/assent
2. Any exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption (such as hormonal contraceptives or hormone replacement therapy [HRT]) within 30 days before informed consent/assent.
3. Known sensitivity to the ingredients in the formulation of IP

Date of first enrolment

12/02/2026

Date of final enrolment

31/12/2026

Locations**Countries of recruitment**

United Kingdom

Australia

Austria

Brazil

Bulgaria

Canada

Czech Republic

France

Germany

Hong Kong

Hungary

Israel

Italy

Japan

Korea, South

Netherlands

New Zealand

North Macedonia

Poland

Portugal

South Africa

Spain

United States of America

Study participating centre

Frimley Health NHS Foundation Trust

Portsmouth Road

Frimley

Camberley

England

GU16 7UJ

Study participating centre

Barts Health NHS Trust

The Royal London Hospital

80 Newark Street

London
England
E1 2ES

Study participating centre

North Bristol NHS Trust

Southmead Hospital
Southmead Road
Westbury-on-trym
Bristol
England
BS10 5NB

Study participating centre

Royal Free London NHS Foundation Trust

Royal Free Hospital
Pond Street
London
England
NW3 2QG

Study participating centre

University Hospitals Plymouth NHS Trust

Derriford Hospital
Derriford Road
Derriford
Plymouth
England
PL6 8DH

Study participating centre

Cambridge University Hospitals NHS Foundation Trust

Addenbrookes Hospital
Cambridge
England
CB2 0AU

Sponsor information

Organisation

Astria Therapeutics, Inc (USA)

Funder(s)

Funder type

Industry

Funder Name

Astria Therapeutics, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date